dr. chi on abiraterone versus enzalutamide for metastatic castration-resistant prostate cancer
Published 7 years ago • 4.9K plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
0:59
dr. crawford on abiraterone versus enzalutamide in prostate cancer
-
4:34
card: cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:53
abiraterone vs docetaxel for metastatic castrate resistant prostate cancer
-
1:34
dr. chi on the titan trial results in metastatic castration-sensitive prostate cancer
-
2:06
dr. chi on androgen deprivation therapy for high-risk metastatic hormone-naive prostate cancer
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide
-
5:37
oral hormonal agents for metastatc castration-resistant prostate cancer
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
1:12
dr. pal on sequencing abiraterone and enzalutamide in mcrpc
-
1:41
dr. oh on abiraterone versus docetaxel in prostate cancer
-
1:12
dr. dreicer on the current role of abiraterone and enzalutamide in prostate cancer
-
2:59
niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
-
5:46
metastatic castration-resistant prostate cancer – new learnings and perspectives
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
2:09
dr. charles ryan discusses abiraterone and enzalutamide for mcrpc
-
1:11
dr. burgess on the synergy between abiraterone and adt in prostate cancer
-
1:55
dr. sweeney on chemotherapy versus abiraterone for mcrpc
-
1:22
dr. bryce on the use of abiraterone versus docetaxel in patients with prostate cancer